<DOC>
	<DOCNO>NCT00557583</DOCNO>
	<brief_summary>The study evaluate safety pharmacokinetics single dos VBY-376 healthy subject .</brief_summary>
	<brief_title>Evaluation Safety Pharmacokinetics Single Doses VBY-376 Healthy Adults</brief_title>
	<detailed_description>Single dose escalation study 5 dose level VBY-376 . Eight subject per group receive one dose VBY-376 multiple blood draw pharmacokinetic evaluation follow safety laboratory evaluation , ECG 's , vital sign , adverse event . Safety data review proceed next dose .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>male females 18 45 year age screen body mass index 20 29 kg/m2 good health clinically significant medical condition able comprehend willing sign inform consent history renal , hepatic impairment , stomach intestinal surgery resection , malabsorption syndrome anemia blood donation within 8 week checkin plasma donation within 4 week checkin history alcoholism drug addiction within 1 year prior checkin use drug abuse tobaccocontaining product within 6 month study participation clinical trial within 30 day history presence abnormal ECG prescription overthecounter medication within 14 day study study history Gilbert 's syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>VBY-376 Hepatitis C pharmacokinetics safety</keyword>
</DOC>